Incidence and Risk Factors for Ocular Surface Disease in Patients Undergoing Glaucoma Medication: A Retrospective Analysis
- 1. Assistant Professor, Department of Ophthalmology, Manipal Tata Medical College, Jamshedpur, Jharkhand
- 2. Assistant Professor, Department of Ophthalmology, Gouri Devi institute of Medical Sciences and Hospital, Durgapur, West Bengal
Description
Background: Untreated glaucoma, a type of chronic ocular neuropathy, can lead to permanent blindness and is a major public health problem around the world. Topical medicines may make Ocular Surface Disease (OSD) worse, which is harmful for both the patient and the treatment, even though lowering intraocular pressure (IOP) is an important part of managing glaucoma. Method: A historical investigation was conducted on 150 glaucoma patients in a tertiary care Eye Hospital in Jamshedpur to determine the prevalence of OSD and the risk factors that increase an individual’s susceptibility to the condition. From the patient’s medical records, information was taken about their background, type of glaucoma, medications, and OSD diagnosis. The results were looked at using both Chi-square testing and logistic regression. Results: In the study group, there was a strong link (p < 0.01) between OSD and primary open-angle glaucoma. Of the people in the group, 45.3% had OSD. Prostaglandin analogs were statistically associated with OSD (p = 0.04). Rates of OSD increased with age among both men and women. Conclusion: A large number of glaucoma patients, close to 50%, have OSD. Individuals with primary open-angle glaucoma and those who use prostaglandin analogs are at a heightened risk. Eliminating OSD is crucial for enhancing glaucoma treatment and prognoses, demonstrating the significance of individualized approaches.
Abstract (English)
Background: Untreated glaucoma, a type of chronic ocular neuropathy, can lead to permanent blindness and is a major public health problem around the world. Topical medicines may make Ocular Surface Disease (OSD) worse, which is harmful for both the patient and the treatment, even though lowering intraocular pressure (IOP) is an important part of managing glaucoma. Method: A historical investigation was conducted on 150 glaucoma patients in a tertiary care Eye Hospital in Jamshedpur to determine the prevalence of OSD and the risk factors that increase an individual’s susceptibility to the condition. From the patient’s medical records, information was taken about their background, type of glaucoma, medications, and OSD diagnosis. The results were looked at using both Chi-square testing and logistic regression. Results: In the study group, there was a strong link (p < 0.01) between OSD and primary open-angle glaucoma. Of the people in the group, 45.3% had OSD. Prostaglandin analogs were statistically associated with OSD (p = 0.04). Rates of OSD increased with age among both men and women. Conclusion: A large number of glaucoma patients, close to 50%, have OSD. Individuals with primary open-angle glaucoma and those who use prostaglandin analogs are at a heightened risk. Eliminating OSD is crucial for enhancing glaucoma treatment and prognoses, demonstrating the significance of individualized approaches.
Files
IJPCR,Vol16,Issue4,Article218.pdf
Files
(715.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:f51a18a300bda4e937dc535a8d01bd3d
|
715.0 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-04-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue4,Article218.pdf
- Development Status
- Active
References
- 1. A. L. Mylla Boso, E. Gasperi, L. Fernandes, V. P. Costa, and M. Alves, "Impact of ocular surface disease treatment in patients with glaucoma," Clinical Ophthalmology, 2020; 103-111. 2. C. Shirai, S. Tsuda, K. Tarasawa, K. Fushimi, K. Fujimori, and T. Nakazawa, "Risk factors leading to trabeculectomy surgery of glaucoma patient using Japanese nationwide administrative claims data: a retrospective noninterventional cohort study," BMC Ophthalmology, 2021; 21: 1-16. 3. C. Shirai, S. Tsuda, K. Tarasawa, K. Fushimi, K. Fujimori, and T. Nakazawa, "Risk factors leading to trabeculectomy surgery of glaucoma patient using Japanese nationwide administrative claims data: a retrospective noninterventional cohort study," BMC Ophthalmology, 2021; 21: 1-16. 4. C. Chamard, S. Larrieu, C. Baudouin, A. Bron, M. Villain, and V. Daien, "Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health in-surance information system, 2008‐2016," Acta Ophthalmologica, 2020; 98(7): e876-e881. 5. S. H. Choi, M. K. Kim, and J. Y. Oh, "Glaucoma after ocular chemical burns: Incidence, risk factors, and outcome," Scientific Reports, 2020; 10(1): 4763. 6. S. Andole and S. Senthil, "Ocular surface disease and anti-glaucoma medications: various features, diagnosis, and management guidelines," Seminars in Ophthalmology, Feb. 2023; 38(2): 158-166. 7. J. Li et al., "Analysis of risk factors associated with secondary open-angle glaucoma in Posner-Schlossman syndrome: A retrospective case-control study," Frontiers in Medicine, 2023; 9: 1064449. 8. J. B. Wingard, D. A. Delzell, N. V. Houlihan, J. Lin, and J. P. Gieser, "Incidence of glaucoma or ocular hypertension after repeated antivascular endothelial growth factor injections for macular degeneration," Clinical Ophthalmology, 2019; 2563-2572. 9. Y. Zhang et al., "Treatment of oculoplastic and ocular surface disease in eyes implanted with a type I Boston Keratoprosthesis in Southern China: a retrospective study," Advances in Therapy, 2020;37:3206-3222. 10. G. Li, E. K. Akpek, and S. Ahmad, "Glaucoma and ocular surface disease: more than meets the eye," Clinical Ophthalmology (Auckland, NZ), 2022; 16: 3641. 11. D. W. Kim, J. H. Seo, and S. H. Lim, "Evaluation of ocular surface disease in elderly patients with glaucoma: expression of matrix metalloproteinase-9 in tears," Eye, 2021; 35(3): 892-900. 12. N. B. Baig et al., "Paediatric glaucoma in Hong Kong: a multicentre retrospective analysis of epidemiology, presentation, clinical interventions, and outcomes," Hong Kong Medical Journal, 2021; 27(1):18. 13. G. Birhanu and A. S. Tegegne, "Predictors for elevation of Intraocular Pressure (IOP) on glaucoma patients; a retrospective cohort study design," BMC Ophthalmology, 2022; 22(1): 254. 14. C. Alvarez-Guzman et al., "Risk factors for secondary Glaucoma in patients with VogtKoyanagi-Harada disease," Journal of Ophthalmic Inflammation and Infection, 2022; 12 (1):22. 15. H. W. Yeh et al., "Association of Glaucoma with the Risk of Peripheral Arterial Occlusive Disease: A Retrospective Population-Based Cohort Study," Journal of Clinical Medicine, 2023; 12(14): 4800.